AB Science hit with FDA warning letter over clinical trials

By Zachary Brennan contact

- Last updated on GMT

AB Science hit with FDA warning letter over clinical trials

Related tags: Clinical trial, Fda

France’s AB Science has received a warning letter from the US FDA for its failure to adhere to agency regulations and to protect trial subjects’ safety in a pancreatic cancer study and GIST (gastrointestinal stromal tumor) studies from 2009 to 2013.

The company is currently running 13 Phase III trials for its lead drug masitinib in a number of oncology indications, as well as for other inflammatory and neurodegenerative diseases.

The warning letter cites the company’s failure to appropriately monitor three protocols which resulted in the inability to identify and correct clinical investigators’ failures to report serious adverse events (SAEs) as specified under the protocols. The company was also cited for failing to perform protocol-required lab tests.

The FDA found that in some cases the unidentified site in question didn’t report the SAEs on the appropriate form, while in other instances it took the site years to report the SAEs.

The FDA also took issue with AB Science’s written response from last October to the Form 483 the FDA previously issued, noting it “is inadequate because your proposed corrective actions make no provisions for assessing the effectiveness of and ensuring sustained compliance with your monitoring practices​.”

Monitoring reports were also not completed and approved within the timeframes specified in the monitoring guidelines, and in some instances, were not completed at all, the FDA found.

In its defense, AB Science said in a statement that it responded to the deviations with “appropriate corrective and preventive actions​,” and that the FDA “did not issue any comment in its letter regarding the relevance of the corrective and preventive actions implemented by AB Science. Rather, the FDA has requested AB Science to detail the activities to: measure the effectiveness of these corrective and preventive actions; [and] ensure the sustained compliance of these corrective and preventive actions.​” On both accounts AB Science says it has responded to the FDA.

The company also said it’s been inspected more than a dozen times by “numerous health authorities and always responded satisfactorily​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars